Denali Therapeutics Shares Are Trading Lower After the Company Announced Topline Results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial Evaluating EIF2B Agonist DNL343 in the Treatment of Amyotrophic Lateral Sclerosis Did Not Meet Its...

Denali Therapeutics的股票在公司宣布Phase 2/3 HEALEY ALS平台试验的G方案的顶线结果后出现下跌，该试验评估了EIF20亿激动剂DNL343在治疗肌萎缩侧索硬化症中的效果，但未达到预期...

Benzinga · 01/07 07:23

Denali Therapeutics Shares Are Trading Lower After the Company Announced Topline Results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial Evaluating EIF2B Agonist DNL343 in the Treatment of Amyotrophic Lateral Sclerosis Did Not Meet Its Primary Endpoint.

Denali Therapeutics的股票在公司公布用于评估治疗肌萎缩性侧索硬化症的第2/3阶段HEALEY ALS平台试验的G方案的主要结果后交易下跌，该试验评估了EIF20亿激动剂DNL343，但未达到其主要终点。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息